Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of Buffered Alendronate in Postmenopausal Osteoporosis
NCT00092027Phase 3Completed
- Sponsor
- Organon & Co.
- Start
- Mar 2003
- Primary completion
- Mar 2004
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in postmenopausal osteoporosis comparing Binosto with Placebo (2 arms). Primary endpoint: Upper Gastrointestinal Safety and Tolerability at 6 months. Started Mar 2003; status: completed.
02
Drugs
alendronate
03
Conditions
postmenopausal osteoporosis
Beyond the preview
Go deeper on NCT00092027.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00092027.